Business
£1.0 million Placing
Nuformix plc has announced a placing to raise gross proceeds of £1.0 million through the issue of 500,000,000 new ordinary shares at 0.20 pence per share. The net proceeds will be used to advance the NXP002 programme, an inhaled treatment for idiopathic and progressive pulmonary fibrosis, by funding additional pre-clinical studies to support out-licensing discussions, and for general corporate purposes. Following admission, expected around March 17, 2026, the total number of ordinary shares in issue will be 2,609,749,903. Disclaimer*
About this update from Nuformix Plc
[{"type":"text","content":"\n\nTHIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.\n \nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"EUWA\")) (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS WHO RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n11 March 2026\n \nNuformix plc\n \n(\"Nuformix\" or the \"Company\" or the \"Group\")\n \n£1.0 million Placing\n \nNuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces a placing (the \"Placing\") to raise gross proceeds of £1.0 million through the issue of 500,000,000 new ordinary shares (\"New Ordinary Shares\") in the capital of the Company at a price of 0.20 pence per share (the \"Issue Price\").\n \nThe net proceeds of the Placing will be used by the Company to drive forward its NXP002 programme, an inhaled treatment for idiopathic pulmonary fibrosis (\"IPF\") and progressive pulmonary fibrosis (\"PPF\") and for general corporate purposes. In particular, the net proceeds will be used to fund a focused programme of additional pre-clinical studies to reinforce areas identified during ongoing out-licensing discussions and due diligence with both large pharmaceutical and speciality pharma partners, and to further advance the NXP002 programme. Whilst completion of the focused studies will represent important value inflection points for the NXP002 programme it is not expected that all the studies will need to conclude for an out-...